Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, and its news flow reflects both its operating performance and corporate developments. Company announcements describe technologies that prioritize preservation and restoration of the patient’s own anatomy and leverage the natural healing response while minimizing long-term exposure to permanent synthetic materials.
News updates for TELA stock frequently include quarterly financial results, where the company reports revenue, gross profit, operating expenses, and net loss, along with commentary on demand for its OviTex and OviTex PRS reinforced tissue matrix products. These releases often discuss factors driving revenue, such as increased unit sales, new customers, international sales, and new product configurations, as well as changes in operating expenses and loss from operations.
Investors can also expect capital markets and financing news, including announcements of credit facilities, registered direct offerings of common stock and pre-funded warrants, and the issuance of warrants in connection with debt agreements. Such updates provide insight into TELA Bio’s liquidity, borrowing arrangements, and intended use of proceeds for sales and marketing, research and development, and other corporate purposes.
Another category of TELA Bio news involves corporate governance and leadership changes, such as appointments of new independent directors with experience in healthcare equity research and executive nursing leadership, as well as board resignations. The company also issues releases about participation in healthcare conferences and inducement grants of restricted stock units and stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4).
By following TELA Bio’s news feed, readers gain timely visibility into the company’s financial performance, product demand trends in soft-tissue reconstruction, capital-raising activities, and changes in board composition and employee equity incentives.
TELA Bio has launched the NIVIS Fibrillar Collagen Pack, enhancing its product portfolio aimed at optimizing soft tissue preservation and restoration. The product, made of Type I and III bovine collagen, is designed for managing moderately to heavily exudating wounds and controlling minor bleeding. Dr. Michael Sawyer noted its effective handling in high-risk surgical wound management. This launch follows TELA's exclusive partnership with Collagen Matrix, Inc. and aligns with its mission to provide advanced soft-tissue reconstruction solutions.
TELA Bio is set to present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 am ET. The company focuses on innovative soft-tissue reconstruction technologies that enhance clinical outcomes by prioritizing the preservation of the patient's anatomy. Interested individuals can access the live and archived webcast through ir.telabio.com. TELA Bio is committed to offering economically effective solutions that utilize the patient's natural healing response, minimizing reliance on synthetic materials.
TELA Bio, Inc. (NASDAQ: TELA) announced the approval of stock options totaling 15,450 shares for 8 new hires as part of their employment compensation on December 7, 2022. The options, granted under Nasdaq Rule 5635(c)(4), have an exercise price of $9.58 per share and a ten-year term, vesting over four years. This strategy emphasizes TELA Bio's commitment to attract talent as it focuses on innovative soft-tissue reconstruction technologies to enhance clinical outcomes.
TELA Bio, a commercial-stage medical technology company, reported a revenue of $11.2 million for Q3 2022, marking a 46% increase year-over-year. The company highlighted rising demand for its OviTex products, achieving 29% and 108% revenue growth for OviTex and OviTex PRS, respectively. They completed a public offering that netted $34.4 million. Despite increased operating expenses totaling $16.8 million, TELA Bio anticipates steady recovery in procedure volumes post-COVID-19 and projects full-year revenue between $42 million and $45 million, representing 43%-53% growth over 2021.
TELA Bio, Inc., a medical technology company, will participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on November 17, 2022, at 1:30 PM ET. The forum aims to showcase innovative soft-tissue reconstruction solutions that prioritize patient anatomy restoration. Interested parties can access the presentation live or archived at ir.telabio.com. TELA's mission focuses on leveraging the patient’s natural healing response while minimizing the use of synthetic materials.
TELA Bio, Inc. announced the approval of inducement grants for 54,600 stock options and 7,500 restricted stock units to 11 new employees. The grants were made under Nasdaq Rule 5635(c)(4) and are part of the new hires' compensation packages as an inducement for their employment. The stock options have an exercise price of $9.00 per share and will vest over four years. The restricted stock units will also vest in equal annual installments over the same period. These equity awards are contingent on continued service with TELA Bio.
TELA Bio, Inc. (TELA) announced it will report its third quarter 2022 financial results on November 9, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on innovative soft-tissue reconstruction solutions, prioritizing patient anatomy preservation. The results will include financial metrics that are crucial for investors. Interested participants need to register in advance to join the call and can access a replay through TELA's investor section online.
TELA Bio announced positive outcomes from the BRAVO Study, showcasing a low recurrence rate of just 2.6% for ventral hernia repairs using OviTex 1S. The two-year study, published in Annals of Medicine and Surgery, involved 92 patients and demonstrated significant improvements in patient quality of life from as early as three months post-surgery. Despite a 38% surgical site occurrence rate among predominantly high-risk patients, the data supports OviTex's efficacy as a viable alternative to traditional synthetic meshes.
TELA Bio, a commercial-stage medical technology company, has announced its participation in two investor conferences. TELA’s management will present virtually at the H.C. Wainwright Annual Global Investment Conference on September 12, 2022, at 7:00 AM ET. Additionally, they will take part in the Lake Street BIG6 1x1 Conference on September 14, 2022. TELA Bio focuses on innovative soft-tissue reconstruction solutions that prioritize patient anatomy preservation. The company is committed to enhancing clinical outcomes while reducing reliance on synthetic materials.
TELA Bio, Inc. is set to participate in the Inaugural Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 8:30 AM ET. This commercial-stage medical technology company focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes by preserving the patient’s anatomy. Interested parties can access the live and archived webcast through the company’s investor relations page. TELA is committed to offering cost-effective technologies that leverage natural healing while minimizing reliance on synthetic materials.